Phase II trial of 5-fluorouracil (NSC-19893), adriamycin (NSC-123127), and methotrexate (NSC-740) in lung adenocarcinoma.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000009:adverse effects; D004317:Doxorubicin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008727:Methotrexate / Q000627:therapeutic use*; D012075:Remission, Spontaneous
D000970:Antineoplastic Agents; D004317:Doxorubicin; D005472:Fluorouracil; D008727:Methotrexate